Matches in SemOpenAlex for { <https://semopenalex.org/work/W2165065963> ?p ?o ?g. }
- W2165065963 endingPage "229" @default.
- W2165065963 startingPage "222" @default.
- W2165065963 abstract "Haematological toxicities and thromboembolic (TE) events are common complications of myeloma therapy. TE risk may be elevated with combination regimens, notably thalidomide/lenalidomide plus high-dose dexamethasone; concomitant erythropoietin appears to further increase the risk with lenalidomide-dexamethasone. We characterised thrombocytopenia and neutropenia in the phase 3 APEX (Assessment of Proteasome Inhibition for Extending Remissions) study of bortezomib versus high-dose dexamethasone in relapsed myeloma, and calculated the incidences of deep-vein thrombosis (DVT)/pulmonary embolism (PE) with: bortezomib or dexamethasone +/- erythropoietin in APEX; bortezomib +/- dexamethasone +/- erythropoietin in two phase 2 studies of relapsed/refractory myeloma. Bortezomib-associated thrombocytopenia and neutropenia were transient, predictable and manageable; mean platelet and neutrophil counts followed a cyclical pattern, and improved over the treatment course. Grade 3/4 thrombocytopenia incidence was higher with bortezomib versus dexamethasone (26%/4% vs. 5%/1%), but significant bleeding events were comparable (4% vs. 5%). DVT/PE incidence was low (< or =3.1%) in all analyses; addition of dexamethasone/erythropoietin did not affect TE risk. In APEX, TE risk appeared lower with bortezomib versus dexamethasone. Bortezomib caused transient and cyclical thrombocytopenia and was not associated with elevated TE risk, alone or with dexamethasone +/- erythropoietin. Preliminary data suggest bortezomib may reduce the thrombogenic potential of combination regimens via inhibition of platelet function or other mechanism-specific effects on coagulation." @default.
- W2165065963 created "2016-06-24" @default.
- W2165065963 creator A5002061358 @default.
- W2165065963 creator A5002972322 @default.
- W2165065963 creator A5020989412 @default.
- W2165065963 creator A5023276777 @default.
- W2165065963 creator A5029569818 @default.
- W2165065963 creator A5031837957 @default.
- W2165065963 creator A5032464400 @default.
- W2165065963 creator A5043526996 @default.
- W2165065963 creator A5057911528 @default.
- W2165065963 creator A5066940168 @default.
- W2165065963 creator A5081233146 @default.
- W2165065963 creator A5090790045 @default.
- W2165065963 date "2008-09-24" @default.
- W2165065963 modified "2023-10-14" @default.
- W2165065963 title "Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma" @default.
- W2165065963 cites W1985658104 @default.
- W2165065963 cites W1992459906 @default.
- W2165065963 cites W1992538067 @default.
- W2165065963 cites W2004349505 @default.
- W2165065963 cites W2015447713 @default.
- W2165065963 cites W2016038211 @default.
- W2165065963 cites W2017303578 @default.
- W2165065963 cites W2021954218 @default.
- W2165065963 cites W2023106232 @default.
- W2165065963 cites W2051305187 @default.
- W2165065963 cites W2051687702 @default.
- W2165065963 cites W2051994734 @default.
- W2165065963 cites W2065859796 @default.
- W2165065963 cites W2069404879 @default.
- W2165065963 cites W207103074 @default.
- W2165065963 cites W2084631110 @default.
- W2165065963 cites W2087384044 @default.
- W2165065963 cites W2090289723 @default.
- W2165065963 cites W2095792323 @default.
- W2165065963 cites W2103660186 @default.
- W2165065963 cites W2107154392 @default.
- W2165065963 cites W2107624227 @default.
- W2165065963 cites W2108235071 @default.
- W2165065963 cites W2113101033 @default.
- W2165065963 cites W2117172636 @default.
- W2165065963 cites W2120161314 @default.
- W2165065963 cites W2124018860 @default.
- W2165065963 cites W2124560610 @default.
- W2165065963 cites W2127206962 @default.
- W2165065963 cites W2131370546 @default.
- W2165065963 cites W2136373453 @default.
- W2165065963 cites W2145412346 @default.
- W2165065963 cites W2148188974 @default.
- W2165065963 cites W2152091753 @default.
- W2165065963 cites W2168592519 @default.
- W2165065963 cites W2168658598 @default.
- W2165065963 cites W2242232812 @default.
- W2165065963 cites W2416048408 @default.
- W2165065963 cites W2442869371 @default.
- W2165065963 cites W2547124264 @default.
- W2165065963 cites W2555212956 @default.
- W2165065963 cites W2580586341 @default.
- W2165065963 cites W2580695821 @default.
- W2165065963 cites W2591392246 @default.
- W2165065963 cites W2594644475 @default.
- W2165065963 cites W2979474503 @default.
- W2165065963 cites W4244478692 @default.
- W2165065963 doi "https://doi.org/10.1111/j.1365-2141.2008.07321.x" @default.
- W2165065963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18713253" @default.
- W2165065963 hasPublicationYear "2008" @default.
- W2165065963 type Work @default.
- W2165065963 sameAs 2165065963 @default.
- W2165065963 citedByCount "87" @default.
- W2165065963 countsByYear W21650659632012 @default.
- W2165065963 countsByYear W21650659632013 @default.
- W2165065963 countsByYear W21650659632014 @default.
- W2165065963 countsByYear W21650659632015 @default.
- W2165065963 countsByYear W21650659632016 @default.
- W2165065963 countsByYear W21650659632017 @default.
- W2165065963 countsByYear W21650659632018 @default.
- W2165065963 countsByYear W21650659632019 @default.
- W2165065963 countsByYear W21650659632020 @default.
- W2165065963 countsByYear W21650659632022 @default.
- W2165065963 countsByYear W21650659632023 @default.
- W2165065963 crossrefType "journal-article" @default.
- W2165065963 hasAuthorship W2165065963A5002061358 @default.
- W2165065963 hasAuthorship W2165065963A5002972322 @default.
- W2165065963 hasAuthorship W2165065963A5020989412 @default.
- W2165065963 hasAuthorship W2165065963A5023276777 @default.
- W2165065963 hasAuthorship W2165065963A5029569818 @default.
- W2165065963 hasAuthorship W2165065963A5031837957 @default.
- W2165065963 hasAuthorship W2165065963A5032464400 @default.
- W2165065963 hasAuthorship W2165065963A5043526996 @default.
- W2165065963 hasAuthorship W2165065963A5057911528 @default.
- W2165065963 hasAuthorship W2165065963A5066940168 @default.
- W2165065963 hasAuthorship W2165065963A5081233146 @default.
- W2165065963 hasAuthorship W2165065963A5090790045 @default.
- W2165065963 hasBestOaLocation W21650659631 @default.
- W2165065963 hasConcept C126322002 @default.
- W2165065963 hasConcept C143998085 @default.
- W2165065963 hasConcept C2776063141 @default.